Delta 9 Cannabis - CEO, John Arbuthnot.
CEO, John Arbuthnot.
Source: Delta 9 Cannabis.
  • Delta 9 Cannabis (DN) has announced the closing of its previously announced overnight marketed financing of units of the company
  • Each unit was offered at $0.22 per equity unit for aggregate gross proceeds of approximately $1,936,006
  • The company will use the net proceeds from the offering for working capital and general corporate purposes
  • Delta 9 Cannabis Inc. is a vertically integrated cannabis company focused on bringing the highest quality cannabis products to market
  • Delta 9 Cannabis Inc. (DN) remains unchanged, trading at $0.21 at 10:45 AM ET

Delta 9 Cannabis (DN) has announced the closing of an overnight marketed financing of units for gross proceeds of $1,936,006.

The offering was conducted and led by Research Capital Corporation as sole agent and sole bookrunner.

The company will use the net proceeds from the offering for working capital and general corporate purposes.

Each equity unit, priced at $0.22, consists of one common share and one common share purchase warrant.

Each warrant entitles the holder to purchase one additional common share at a price of $0.255 for up to 36 months.

The offering is subject to the final approval of the Toronto Stock Exchange.

Delta 9 Cannabis is a cannabis company focused on bringing the highest quality cannabis products to market. Delta 9’s wholly-owned subsidiary, Delta 9 Bio-Tech Inc., is a licensed producer of medical and recreational cannabis and operates an 80,000 square foot production facility in Winnipeg, Manitoba. Delta 9 owns and operates a chain of retail stores under the Delta 9 Cannabis Store brand.

Delta 9 Cannabis Inc. (DN) remains unchanged, trading at $0.21 at 10:49 AM ET.

More From The Market Online

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.

The Market Online’s Weekly Cannabis Report – May 10, 2024

A leading North American cannabis and consumer packaged goods company will acquire key players in its U.S. expansion strategy.